Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.59 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5869606 | 1.00 | SLC6A4 (0.59) | SLC6A4SLC6A2CYP2D6NOS2MEN1 | |
| Hydrochloric Acid SCHEMBL5869234 | 0.85 | SLC6A4 (0.59) | SLC6A4SLC6A2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5869256 | 0.85 | SLC6A4 (0.59) | SLC6A4SLC6A2CYP2D6MEN1KMT2A | |
| Oxalic Acid SCHEMBL6561979 | 0.81 | MRGPRX4 (0.42) | SLC6A4MEN1KMT2ARAB9A | |
| SCHEMBL23521652 | 0.81 | CACNA2D1 (0.67) | SLC6A4SLC6A2CYP2D6KMT2ACYP2C19 | |
| SCHEMBL21742715 | 0.81 | CACNA2D1 (0.67) | SLC6A4SLC6A2CYP2D6KMT2ACYP2C19 | |
| SCHEMBL5869336 | 0.80 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5869711 | 0.80 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5869414 | 0.79 | MRGPRX4 (0.41) | SLC6A4MEN1KMT2A | |
| SCHEMBL5869614 | 0.79 | MRGPRX4 (0.41) | SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | SLC6A4 7/4885OPRM1 23/4885SLC6A2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.